reported that the baseline frequency of PD-1+ EOMES+ CD8 T cells was significantly higher in NSCLC patients with progressive disease than in NSCLC patients with controlled disease prior to receiving nivolumab therapy.52 This evidence concerns the gene CD8A and non-small cell lung carcinoma.